Full Breakdown
Sanofi's Leadership Change: Paul Hudson Ousted, Belén Garijo Appointed CEO
2/12/2026, 2:37:34 PM
Sudden Leadership Transition at Sanofi
Sanofi, the French pharmaceutical giant, has announced the abrupt ousting of CEO Paul Hudson, effective February 17, 2026. The company has appointed Belén Garijo, the current CEO of Merck KGaA, to succeed him starting April 29, 2026. This decision comes amid increasing pressure on Sanofi due to disappointing clinical trial results and a stalled turnaround strategy since Hudson took over in 2019.
Background on Paul Hudson's Tenure
Paul Hudson was brought on board with a mandate to revitalize Sanofi's drug pipeline and reduce its reliance on its leading product, Dupixent, an asthma and skin disease treatment. Despite his efforts to boost research and development (R&D) spending, the company faced significant challenges, including mixed results from key late-stage trials and a decline in stock performance—Sanofi shares have dropped 21% over the past year. Analysts noted that Hudson's strategies did not yield the expected rapid results, leading to frustration among investors.
Belén Garijo's Appointment and Expectations
Belén Garijo, who has a long history with Sanofi, having spent 15 years at the company, is expected to bring a renewed focus on R&D productivity and strategic execution. Sanofi Chairman Frédéric Oudea expressed confidence in Garijo's ability to lead the company into its next growth phase, emphasizing her experience and profile as critical to accelerating the company's strategy. Analysts predict that Garijo will implement greater discipline in operations and enhance the company's innovation capacity.
Criticism of Hudson's Leadership
Critics have pointed to Hudson's inability to deliver on key targets, particularly in transforming Sanofi's historically poor R&D productivity and finding a successor for Dupixent. The company has struggled with a series of underwhelming trial updates and has been criticized for its reliance on acquisitions to drive growth. Hudson's leadership style, while aimed at modernizing the company, has not translated into the desired financial performance, as evidenced by Sanofi's lower shareholder returns compared to competitors like AstraZeneca and GSK.
Official Statements and Future Outlook
In a statement regarding the leadership change, Sanofi highlighted the need for a new direction to navigate the challenges ahead, particularly as Dupixent's patent protection is set to expire in the early 2030s. Analysts suggest that Garijo's leadership will be pivotal in addressing these challenges and revitalizing the company's R&D efforts.
Verbatim Quotes
- “Investors remain frustrated with the repeated R&D failures,” — Abhishek Raval, Analyst at AlphaValue
- “She has the experience and profile to accelerate the pace, strengthen the quality of execution of strategy and lead the next growth cycle of the company,” — Frédéric Oudea, Sanofi Chairman
- “Sanofi’s earnings multiple nevertheless trailed peers and its shares underperformed though 2025 as he failed to deliver on his key targets to transform historically poor R&D productivity and find a replacement for lead drug Dupixent.” — Jefferies Analyst Michael Leuchten
As Sanofi prepares for this transition, the focus will be on how Garijo can leverage her experience to enhance the company's performance and address the pressing challenges in the pharmaceutical landscape.
